WO2003074086A1 - Matrice liquide a transfert de phase in vivo, et preparations liquides orales - Google Patents

Matrice liquide a transfert de phase in vivo, et preparations liquides orales Download PDF

Info

Publication number
WO2003074086A1
WO2003074086A1 PCT/JP2003/002410 JP0302410W WO03074086A1 WO 2003074086 A1 WO2003074086 A1 WO 2003074086A1 JP 0302410 W JP0302410 W JP 0302410W WO 03074086 A1 WO03074086 A1 WO 03074086A1
Authority
WO
WIPO (PCT)
Prior art keywords
liquid
oral preparations
vivo
phase transfer
undergoing phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2003/002410
Other languages
English (en)
French (fr)
Inventor
Hideakira Yokoyama
Akihiko Hirata
Hidetoshi Hamamoto
Keiko Yamazaki
Takeru Fujii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedRx Co Ltd
Original Assignee
MedRx Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedRx Co Ltd filed Critical MedRx Co Ltd
Priority to EP03743551A priority Critical patent/EP1488812A4/en
Priority to KR10-2004-7012535A priority patent/KR20040089628A/ko
Priority to CA002477964A priority patent/CA2477964A1/en
Priority to AU2003211627A priority patent/AU2003211627A1/en
Priority to US10/506,512 priority patent/US20050089577A1/en
Publication of WO2003074086A1 publication Critical patent/WO2003074086A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2003/002410 2002-03-04 2003-03-03 Matrice liquide a transfert de phase in vivo, et preparations liquides orales Ceased WO2003074086A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP03743551A EP1488812A4 (en) 2002-03-04 2003-03-03 PHASE TRANSFER OF LIVING MATERIAL IN VIVO AND LIQUID ORAL PREPARATIONS
KR10-2004-7012535A KR20040089628A (ko) 2002-03-04 2003-03-03 생체내에서 상전이하는 액상 매트릭스 및 액상 경구 제제
CA002477964A CA2477964A1 (en) 2002-03-04 2003-03-03 Liquid matrix transforming its phase in living body and oral liquid preparation
AU2003211627A AU2003211627A1 (en) 2002-03-04 2003-03-03 Liquid matrix undergoing phase transfer in vivo and liquid oral preparations
US10/506,512 US20050089577A1 (en) 2002-03-04 2003-03-03 Liquid matrix undergoing phase transfer in vivo and liquid oral preparations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002/57943 2002-03-04
JP2002057943 2002-03-04

Publications (1)

Publication Number Publication Date
WO2003074086A1 true WO2003074086A1 (fr) 2003-09-12

Family

ID=27784679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/002410 Ceased WO2003074086A1 (fr) 2002-03-04 2003-03-03 Matrice liquide a transfert de phase in vivo, et preparations liquides orales

Country Status (7)

Country Link
US (1) US20050089577A1 (ja)
EP (1) EP1488812A4 (ja)
KR (1) KR20040089628A (ja)
CN (1) CN1638804A (ja)
AU (1) AU2003211627A1 (ja)
CA (1) CA2477964A1 (ja)
WO (1) WO2003074086A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065659A1 (en) * 2003-12-22 2005-07-21 Mcneil-Ppc, Inc. Consumer customized dosage forms

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006129386A1 (ja) * 2005-06-03 2006-12-07 Medrx Co., Ltd. 経口腸溶性医薬組成物
US20070082115A1 (en) * 2005-10-07 2007-04-12 Aimutis William Ronald Jr Methods for inducing satiety, reducing food intake and reducing weight
US20070082107A1 (en) * 2005-10-07 2007-04-12 Aimutis William R Jr Compositions and methods for reducing food intake and controlling weight
US20070082108A1 (en) * 2005-10-07 2007-04-12 Aimutis William R Jr Methods for reducing calorie intake
US20070082085A1 (en) * 2005-10-07 2007-04-12 Catani Steven J Compositions and methods for reducing food intake and controlling weight
US7812082B2 (en) * 2005-12-12 2010-10-12 Evonik Stockhausen, Llc Thermoplastic coated superabsorbent polymer compositions
WO2007117605A2 (en) * 2006-04-06 2007-10-18 Taro Pharmaceuticals North America, Inc. Novel spill-resistant formulations comprising hydrocolloidal polymers
ATE544356T1 (de) * 2006-08-24 2012-02-15 Unilever Nv Flüssige, das völlegefühl verstärkende zusammensetzung
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
PH12013500477A1 (en) 2010-09-13 2018-01-17 Bev Rx Inc Aqueous drug delivery system comprising off-flavor masking agent
KR20120108218A (ko) * 2011-03-23 2012-10-05 동아제약주식회사 위식도 역류질환 치료용 액상 타입 조성물
PT2939551T (pt) * 2012-12-25 2021-04-01 Taisho Pharmaceutical Co Ltd Bebida gasosa à base de água
US9993497B2 (en) * 2012-12-30 2018-06-12 Hadasit Medical Research Services And Development Ltd. Use of alginate compositions in preventing or reducing liver damage caused by a hepatotoxic agent
AU2015253188B2 (en) * 2014-04-29 2017-09-28 The Procter & Gamble Company Bismuth-containing liquid pharmaceutical suspensions
CN106255495B (zh) 2014-04-29 2019-10-22 宝洁公司 用于制备含铋的液体药物悬浮液的方法
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
WO2023018661A1 (en) * 2021-08-10 2023-02-16 Bayer Healthcare Llc Liquid formulations comprising alginic acid, pectin, and carrageenan and methods of using thereof
WO2023018649A1 (en) * 2021-08-10 2023-02-16 Bayer Healthcare Llc Liquid formulations comprising alginic acid, pectin, and carrageenan and methods of using thereof for gastric and gastroesophageal disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4621672B1 (ja) * 1968-04-18 1971-06-19
JPS5283964A (en) * 1976-01-01 1977-07-13 Uoonaa Ramubaato Co Acid sensitive vihicle for medicine
JPS58152820A (ja) * 1982-03-04 1983-09-10 Kyosei Seiyaku Kk 癌治療用組成物
WO1988007862A1 (en) * 1987-04-08 1988-10-20 Farma Food A/S An antacid composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4717713A (en) * 1983-10-31 1988-01-05 Research Corporation Controlled release liquid pharmaceutical
US4744986A (en) * 1986-03-07 1988-05-17 Rorer Pharmaceutical Corporation Process for the preparation of a viscosity-stable antacid composition
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
US5409903A (en) * 1992-02-18 1995-04-25 Urecap Corporation Method and compositions for the treatment of H. pylori and dermatitis
US5447918A (en) * 1992-07-27 1995-09-05 Mccullough; Ricky W. Gastrointestinal anti-irritant composition comprising sucralfate and methods of use
AU6426994A (en) * 1993-03-16 1994-10-11 Synepos Aktiengesellschaft Aluminium containing pharmaceutical preparation with controlled release
JP2004503601A (ja) * 2000-07-13 2004-02-05 ファルマシア・コーポレーション 眼のｃｏｘ−２媒介疾患の処置及び予防におけるｃｏｘ−２阻害剤の使用法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4621672B1 (ja) * 1968-04-18 1971-06-19
JPS5283964A (en) * 1976-01-01 1977-07-13 Uoonaa Ramubaato Co Acid sensitive vihicle for medicine
JPS58152820A (ja) * 1982-03-04 1983-09-10 Kyosei Seiyaku Kk 癌治療用組成物
WO1988007862A1 (en) * 1987-04-08 1988-10-20 Farma Food A/S An antacid composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1488812A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065659A1 (en) * 2003-12-22 2005-07-21 Mcneil-Ppc, Inc. Consumer customized dosage forms
US7371405B2 (en) 2003-12-22 2008-05-13 Mcneil-Ppc, Inc. Consumer customized dosage forms

Also Published As

Publication number Publication date
CN1638804A (zh) 2005-07-13
US20050089577A1 (en) 2005-04-28
EP1488812A4 (en) 2006-05-03
CA2477964A1 (en) 2003-09-12
EP1488812A1 (en) 2004-12-22
AU2003211627A1 (en) 2003-09-16
KR20040089628A (ko) 2004-10-21

Similar Documents

Publication Publication Date Title
WO2003074086A1 (fr) Matrice liquide a transfert de phase in vivo, et preparations liquides orales
EP2168962A3 (en) Phenylacetamides and their use as glucokinase modulators
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
MXPA05008909A (es) Formulacion intranasal de rotigotina.
WO2002066016A3 (de) Mucoadhäsive zerfallsfähige arzneizubereitung
HUP0101580A2 (hu) Gélesedő gyógyászati készítmények
HUP0101512A2 (hu) Adhéziós mikrogyöngy hatóanyag-adagoló készítmény, eljárás az előállítására és a készítményt tartalmazó eszköz
WO2002045683A3 (en) Reversible gelling system for ocular drug delivery
CA2303498A1 (en) Dioxocyclopentyl hydroxamic acids
NZ501950A (en) Medicinal compositions for application to mucosa
TW200514590A (en) Hydrophilic adhesives for delivery of herbal medicines
BR9901782A (pt) Forma para dosagem de nefazodona.
CN110461374A (zh) 电化学气体递质生成组合物及其使用方法和敷料以及包含其的治疗系统
BR0212155A (pt) Composição farmacêutica
AU5326098A (en) Benzofuranacrylic acid derivatives and their use as modulators of RXRS or RARS receptors
JP5430146B2 (ja) 身体貼付用シート剤
ATE444739T1 (de) Polymerzusammensetzung sowie diese enthaltende darreichungsformen
US20080081056A1 (en) Depolymerized polysaccharide-based hydrogel adhesive and methods of use thereof
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
BR9912533A (pt) Composição farmacêutica tendo sabor melhorado
ATE390127T1 (de) Universelle zusammensetzung zur kontrollierten wirkstoffabgabe enthaltend chitosan
SE0001916D0 (sv) Novel formulation
IT1306643B1 (it) Processo per la preparazione dei composti autoreticolati dell'acidoialuronico e dei suoi derivati ottenibili mediante la tecnica
EP1560566B1 (en) Controlled and continued delivery of rifaximin
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1020047012535

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2477964

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 20038052598

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003743551

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10506512

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003743551

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003743551

Country of ref document: EP